Congruence Therapeutics Raises $39.5 Million in New Funding
Congruence Therapeutics, a Montreal-based company specializing in drug discovery through protein dynamics and computational chemistry, has announced the successful closure of a $39.5 million funding round. The round was led by Dimension, with participation from notable investors including OrbiMed, Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital's Thrive Venture Fund, Driehaus, and Silver Arc.
Company Overview
Founded by Katherine Bonter, Executive Director IP, and Michael-Rock Goldsmith, Ph.D., Chief Innovation Scientist, Congruence Therapeutics is leveraging the power of machine learning and biophysics to address diseases caused by protein misfolding. This innovative approach aims to develop small molecule correctors that can restore normal protein function.
Use of Funds
The newly acquired funds will be directed towards advancing Congruence’s lead program, CGX-926, which is currently undergoing a Phase 1/1b clinical trial. This trial is testing the treatment for MC4R-deficient genetic obesity, involving both healthy participants and patients with the condition. Additionally, the company plans to carry out IND-enabling activities for two more programs targeting GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin deficiency. Regulatory filings for these initiatives are anticipated in early 2027.
Moreover, Congruence will continue to develop its proprietary Revenir™ platform, which utilizes computational drug discovery to identify novel binding opportunities for small molecule therapies.
Collaborative Efforts
Beyond its internal projects, Congruence is expanding its collaborative initiatives. This includes an extended partnership with Ono Pharmaceutical, exploring therapeutic areas such as oncology, neurology, and immunology. The company is also engaged with another global pharmaceutical partner on a metabolic disease target.
Leadership Insights
Clarissa Desjardins, Co-Founder and CEO of Congruence Therapeutics, commented on the funding: "Our mission is to translate biology, chemistry and protein structural insights into medicines that address disease at its molecular origin. In addition to CGX-926, we are advancing multiple proprietary and collaborative programs. We thank our new and existing investors for their continued support."
With this substantial investment, Congruence Therapeutics is well-positioned to enhance its research and development efforts, potentially bringing groundbreaking treatments to market for diseases rooted in protein misfolding.